# Big Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/big-health

- Industry: Healthcare
- Headquarters: San Francisco, US
- Website: www.bighealth.com
- Total disclosed funding: $117M
- Latest round: Series C (Jan 19, 2022)
- Investors on record: 9

## About

Founded in 2010 in San Francisco, US, Big Health Inc develops digital solutions for mental health. The company was co-founded by Peter Hames and Colin A. Espie
while Yael Berman serves as a CEO as of 2026. In February 2026, Big Health Inc raised USD 23.7 million in venture funding co-led by .406 Ventures and AlleyCorp, with participation from CVS Health Ventures, BlueCross BlueShield Venture Partners, Sandbox Industries, Supermoon Capital and Gilde Healthcare. 

Big Health offers a comprehensive suite of digital mental health programs designed to enhance the well-being of users facing various mental health challenges, specifically targeting generalized anxiety disorder, sleep issues, and low mood. Their core product offerings include Sleepio, a program aimed at improving sleep quality through cognitive and behavioral techniques; Daylight, which helps individuals manage anxiety and worry; and Spark Direct, focused on enhancing mood and overall well-being. These digital solutions are accessible anytime and anywhere, providing users with the ability to engage with mental health care without the traditional barriers associated with in-person therapy. Big Health serves a diverse client base that includes employers, health plans, and benefit consultants primarily in the United States, with plans to expand into additional international markets.

The revenue model for Big Health is primarily based on a subscription structure, where organizations such as employers and health plans pay for access to their mental health programs. This business-to-business model allows companies to offer these valuable resources as part of their employee benefits packages, enhancing the mental health support available to their workforce. Transactions typically involve a partnership agreement, where the client pays a set fee for the use of flagship products like Sleepio, Daylight, and Spark Direct, thereby providing their employees with access to these digital mental health solutions. Specific pricing plans are aligned with the needs of the organizations they serve, with options available for different scales of deployment to suit various client sizes, from small businesses to large enterprises.

The company will use the February 2026 funding to accelerate the commercialization and adoption of its FDA-cleared digital therapeutics, expand strategic provider partnerships, strengthen integration of its solutions into clinical workflows, and increase patient access to its treatments for insomnia and anxiety. The investment will also support scaling the company's growth, expanding market penetration, and capitalizing on new reimbursement opportunities for digital mental health treatments.

## Funding rounds

- Series C, Jan 19, 2022, $75M — Gilde Healthcare, 5Y Capital, ArrowMark Partners, Kaiser Permanente Ventures, Octopus Investments, SB Investment Advisers
- Series B, Jun 18, 2020, $39M — Gilde Healthcare, 5Y Capital, Kaiser Permanente Ventures, Octopus Investments, Samsung NEXT Ventures
- Series A, Apr 28, 2014, $3.3M — Index Ventures, Forward Partners

## Investors

- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Series A
- Forward Partners (https://capitalatlas.ai/funds/forward-partners) — Series A
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series B, Series C
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B, Series C
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series B, Series C
- Octopus Investments (https://capitalatlas.ai/funds/octopus-investments) — Series B, Series C
- Samsung NEXT Ventures (https://capitalatlas.ai/funds/samsung-next-ventures) — Series B
- ArrowMark Partners — Series C
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series C